Head to head

CJC-1295 with DAC vs GHRP-2

GH secretagogue

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Usually stacked — and GHRP-2 rests on firmer evidence

CJC-1295 with DAC and GHRP-2 appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you are picking one, the evidence is the honest tiebreak: GHRP-2 has approval from a regulator somewhere, though not a current FDA or EMA label, while CJC-1295 with DAC has some human data, but it is small, old, or uncontrolled. That is a difference in how much is known, not a verdict on how well either works.

What you are actually choosing between

Before anything else: the dataset lists CJC-1295 with DAC and GHRP-2 in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is muscle growth and recovery and sleep. On this site's goal weighting — an editorial priority score, not a measure of effect size — CJC-1295 with DAC rates 4/5 for muscle growth and GHRP-2 rates 3/5. Outside that overlap only GHRP-2 goes further, carrying weight for appetite control; CJC-1295 with DAC's declared goals stop at the overlap.

The evidence

This is the part that decides most of it. GHRP-2 has approval from a regulator somewhere, though not a current FDA or EMA label — registered in Japan as pralmorelin for a single-dose diagnostic test, not chronic use. CJC-1295 with DAC has some human data, but it is small, old, or uncontrolled — phase 1 single-dose studies only; development was discontinued. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

CJC-1295 with DAC is a subcutaneous injection; GHRP-2 is a subcutaneous injection and an intramuscular injection. Both are injected, so route does not decide this one.

Kinetics are not close. CJC-1295 with DAC has a half-life of 7 days against GHRP-2's 1 h — more than two orders of magnitude — which is why one is dosed once a week and the other once daily. A long half-life means a steadier level and a mistake you cannot take back for days; a short one means timing matters and a bad day washes out fast.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

CJC-1295 with DAC

Dosed once weekly at 1 to 2 mg, which is how it is overwhelmingly run in practice: the albumin binding makes the weekly total the meaningful quantity, and splitting it across the week buys nothing. A GHRH (1-29) analogue carrying a Drug Affinity Complex maleimide that binds serum albumin, which is the ONLY reason it differs from the no-DAC version: the terminal half-life runs roughly 6 to 8 days instead of minutes, so a single dose produces a sustained rise in GH and IGF-1 rather than a discrete pulse. Phase 1 human dosing studies used single subcutaneous doses of about 30 to 250 mcg/kg. Development was discontinued and it is NOT approved by any regulator; consumer supply is research-chemical grade. Because exposure is continuous rather than pulsatile, it is the less physiologic of the two CJC-1295 forms and carries more of the water-retention and glucose signal.

GHRP-2

Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist. Unusually for this corner of the market it has real human data: it has been studied as a growth hormone secretagogue in published dose-response work, and the same molecule is registered in Japan as pralmorelin for use as a single-dose diagnostic test of growth hormone deficiency. That diagnostic use is a one-off intravenous challenge, not a chronic subcutaneous protocol, so the human evidence supports the fact that it releases growth hormone rather than the community habit of dosing it daily for months. It is not approved for physique or anti-ageing use anywhere. It is less selective than ipamorelin: expect measurable prolactin and cortisol elevation, which is the usual reason people switch away from it. The 100-300 mcg per dose range, often split into two or three doses a day, comes from practice rather than from a label.

Side by side

The numbers

CJC-1295 with DAC compared with GHRP-2
Attribute	CJC-1295 with DAC	GHRP-2
Class	GH secretagogue	GH secretagogue
Routes	Subcutaneous	Subcutaneous, Intramuscular
Dose range	1 mg–2 mg (typical 1.5 mg)	100 mcg–300 mcg (typical 200 mcg)
Frequency	Once a week	Once daily
Half-life	7 days	1 h
Cycle length	12 weeks	12 weeks
Experience	Intermediate	Intermediate
Evidence	Limited human data	Approved elsewhere
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Water retention and puffiness, more pronounced than with short-acting GHRHs Injection site redness or swelling Head rush, flushing or transient dizziness Tingling or numbness in the hands, which can reflect carpal tunnel pressure Reduced insulin sensitivity and higher fasting glucose with sustained elevation Lethargy or headache, often reported in the first week	Raises prolactin and cortisol more than ipamorelin does — this is its main practical drawback, and it scales with dose, so pushing past roughly 300 mcg per injection buys little extra growth hormone while making the hormonal spillover worse Hunger spike within about half an hour of dosing, which works against a cut Water retention, morning puffiness, and numb or tingling hands Head rush, flushing or brief light-headedness just after injection Blunted response over months of uninterrupted daily use, so it is usually cycled Injection site redness or itching

Turn a typical dose into a mark on the syringe: CJC-1295 with DACGHRP-2

Goals

Where they overlap, and where they do not

Goal	CJC-1295 with DAC	GHRP-2
muscle growth	CJC-1295 with DAC: 4/5	GHRP-2: 3/5
recovery and sleep	CJC-1295 with DAC: 3/5	GHRP-2: 3/5
injury repair	CJC-1295 with DAC: 3/5	GHRP-2: 2/5
fat loss	CJC-1295 with DAC: 2/5	GHRP-2: 2/5
longevity	CJC-1295 with DAC: 2/5	GHRP-2: 1/5
appetite controlone only	CJC-1295 with DAC: —	GHRP-2: 3/5

They overlap on 5 goals and diverge on 1. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCJC-1295 with DACMechanism, protocol, storage, sources.MonographGHRP-2Mechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.